A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive
Sponsor: Bristol-Myers Squibb
This PHASE1/PHASE2 trial investigates Hepatitis B, Chronic and is currently completed. Bristol-Myers Squibb leads this study, which shows 10 recorded versions since 2007 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .